TransMedics: I'm More Bullish Than Ever

Core Insights - TransMedics (NASDAQ: TMDX) has been rated as a "Strong Buy" in previous analyses, with a 46% increase in stock value since November 2024, but a 3% decline since May 2025 [1] Group 1: Company Overview - TransMedics is focused on innovative solutions in the organ transplant sector, with a long-term investment perspective of 3-5 years [1] - The company has garnered attention for its potential to significantly impact the organ transplant market, which is critical for patient outcomes [1] Group 2: Analyst Background - MMMT Wealth, managed by Oliver, a CPA with experience in private equity and asset management, emphasizes thorough research and analysis of investment opportunities [1] - Oliver's investment philosophy is driven by the belief that a few well-chosen investments can lead to substantial financial changes in an investor's life [1]